J Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in
|
|
- Alaina Hart
- 5 years ago
- Views:
Transcription
1 VOLUME 22 NUMBER 12 JUNE JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian, Nadine Tung, Ivo Olivotto, Ellen Warner, Olufunmilayo I. Olopade, Andrea Eisen, Barbara Weber, Jane McLennan, Ping Sun, William D. Foulkes, and Steven A. Narod From the Faculty of Nursing and the Centre for Research on Women s Health, and Sunnybrook and Women s College Health Sciences Centre, University of Toronto; Toronto Sunnybrook Regional Cancer Centre, Toronto; Epidemiology Research Unit, Centre Hospitalier de Université de Montreal (CHUM); Program in Cancer Genetics, McGill University, Montreal; British Columbia Cancer Agency, Vancouver; Hamilton Regional Cancer Centre, Hamilton, Canada; Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE; Beth Israel Deaconess Medical Center, Boston, MA; Department of Medicine, University of Chicago, Chicago, IL; Departments of Medicine and Genetics, Department of Hematology/ Oncology, University of Pennsylvania, Philadelphia, PA; Cancer Risk Program, UCSF Comprehensive Cancer Center, San Francisco, CA. Submitted April 3, 2003; accepted March 24, A B S T R A C T Purpose To estimate the risk of contralateral breast cancer in BRCA1 and BRCA2 carriers after diagnosis and to determine which factors are predictive of the risk of a second primary breast cancer. Patients and Methods Patients included 491 women with stage I or stage II breast cancer, for whom a BRCA1 or BRCA2 mutation had been identified in the family. Patients were followed from the initial diagnosis of cancer until contralateral mastectomy, contralateral breast cancer, death, or last follow-up. Results The actuarial risk of contralateral breast cancer was 29.5% at 10 years. Factors that were predictive of a reduced risk were the presence of a BRCA2 mutation (v BRCA1 mutation; hazard ratio [HR], 0.73; 95% CI, 0.47 to 1.15); age 50 years or older at first diagnosis (v 49 years; HR, 0.63; 95% CI, 0.36 to 1.10); use of tamoxifen (HR, 0.59; 95% CI, 0.35 to 1.01); and history of oophorectomy (HR, 0.44; 95% CI, 0.21 to 0.91). The effect of oophorectomy was particularly strong in women first diagnosed prior to age 49 years (HR, 0.24; 95% CI, 0.07 to 0.77). For women who did not have an oophorectomy or take tamoxifen, the 10-year risk of contralateral cancer was 43.4% for BRCA1 carriers and 34.6% for BRCA2 carriers. Conclusion The risk of contralateral breast cancer in women with a BRCA mutation is approximately 40% at 10 years, and is reduced in women who take tamoxifen or who undergo an oophorectomy. J Clin Oncol 22: by American Society of Clinical Oncology Authors disclosures of potential conflicts of interest are found at the end of this article. Address reprint requests to Steven Narod, MD, Centre for Research on Women s Health, Women s College Hospital, 790 Bay St, Room 750, Toronto, Ontario, Canada M5G 1N8; steven.narod@sw.ca by American Society of Clinical Oncology X/04/ /$20.00 DOI: /JCO INTRODUCTION Women who carry a germline mutation in either the BRCA1 or BRCA2 gene face a high lifetime risk of breast cancer, 1 and, once diagnosed with breast cancer, face a high risk of subsequently developing cancer in the contralateral breast. 2-7 As a result, women may opt for contralateral mastectomy as a preventive measure as part of their initial treatment. It is not clear to what extent the risk of contralateral breast cancer varies with age, and if the risk is equivalent for carriers of BRCA1 and BRCA2 mutations. Factors that modify the risk of contralateral breast cancer in BRCA carriers have not been studied prospectively. In a case-control study, 8 we found that the risk of contralateral breast cancer in BRCA carriers was reduced if the woman had taken tamoxifen (hazard ratio [HR], 0.50; 95% CI, 0.28 to 0.89), if she had had an oophorectomy (HR, 0.42; 95% CI, 0.22 to 0.83), or if she had received chemotherapy (HR, 0.40; 95% CI, 0.26 to 0.60). However, it was not possible to estimate the actuarial risk for contralateral breast cancer or to study the possible effect of age at diagnosis on contralateral breast cancer risk. Here we present data from a large-scale prospective study designed to generate estimates of the risk of contralateral breast cancer among women with BRCA1 or BRCA2 mutations, and to identify host- and treatment-related factors that might modify the risk. 2328
2 BRCA Mutations and Contralateral Breast Cancer PATIENTS AND METHODS Study Subjects Pedigrees of cancer families identified at 10 participating cancer genetics clinics were reviewed. A family was considered to be eligible for the study when a BRCA1 or a BRCA2 mutation was documented in the family, and at least one case of invasive breast cancer was recorded. Eligible study subjects included all women from these families who were diagnosed with stage I or stage II breast cancer at age 65 years or younger, between 1975 and Living and deceased women were eligible, but those with a prior diagnosis of cancer (including breast cancer) or those who resided outside of North America were excluded. It was not necessary to be a proven carrier of the mutation found in the family to be included in the study; however, affected women who were known to be noncarriers were excluded. All study procedures were approved by the institutional review boards at each of the participating centers. We identified a total of 1,139 breast cancer cases in 337 families. Of the total of 1,139 cases of breast cancer, 320 women were excluded because the date of diagnosis indicated on the pedigree was before 1975, and 50 women were excluded because the age of diagnosis was older than 65 years. An additional 19 women were not carriers of the familial mutation and were therefore excluded. Ten women were excluded because they had a diagnosis of other cancer before breast cancer, and 11 women were excluded because they were treated outside of North America. We were able to obtain identifying information for 587 of the remaining 729 women (80.5%). An attempt was made to contact each of these women or their respective next-of-kin to obtain permission to review the medical records. Thirteen women (or their next of kin) refused to provide consent for the release of their medical records. The medical record was requested from the hospital where treatment was received for the remaining 574 women. In 54 cases, the hospital was not able to locate the record or did not forward the requested documents. The medical record was obtained for the remaining 520 women (91%). After review of the medical records, an additional 29 women were excluded. Of these, 22 women were excluded because tumor stage was greater than 2, six women were excluded because the tumor was noninvasive (ductal carcinoma in situ or lobular carcinoma in situ), and one woman was excluded because she refused treatment. The remaining 491 women were included in the analysis. In summary, of the 1,139 breast cancers, 439 were ineligible, and we were able to enroll 491 of the remaining 700 eligible cases (70%). Ninety-two (18.7%) of the 491 women were deceased. Study Protocol The medical treatment records and pathology documents were reviewed. We established whether the tumor was unilateral (482 cases) or bilateral (nine cases) at initial diagnosis. We recorded tumor size (in centimeters), nodal status (positive or negative), and tumor grade (I to III). Where possible, we abstracted information on both mitotic grade and nuclear grade. Estrogen receptor status was recorded as positive, negative, or equivocal. We recorded the use of chemotherapy (yes or no), tamoxifen (yes or no), and radiotherapy (yes or no). We established whether or not the patient had undergone a bilateral oophorectomy, and if so, the date of the operation. We categorized the principal surgery as either breast-conserving surgery (ie, lumpectomy), unilateral mastectomy, or bilateral mastectomy. In some cases, the contralateral mastectomy and/or oophorectomy were performed several years after the initial surgical treatment; the dates of these late treatments were recorded. We reviewed the medical records of deceased women to establish the cause of death. Because of the relatively young ages of death of these women (mean age, 48.0 years; range, 31.5 to 84.1 years), the great majority of deaths in the cohort were due to breast or ovarian cancer. We reviewed the dates of diagnosis of all contralateral breast cancers reported in the cohort. Only invasive contralateral cancers were included. Contralateral breast cancers were assumed to be new primary breast cancers and not metastases of the original primary. No woman was diagnosed with contralateral breast cancer after she was diagnosed with distal metastases. Statistical Analysis A survival analysis was performed. We considered the woman to be at risk for contralateral breast cancer from the date of the first surgical procedure until either death from breast or ovarian cancer, death from another cause, or the date of last follow-up. Initially, we compared the risk of contralateral breast cancer in women who had and who did not have a contralateral mastectomy. In subsequent analyses, only women for whom the contralateral breast was intact were considered to be at risk for contralateral breast cancer. Survival curves were constructed and compared for subgroups of women defined by age ( 40 years; 41 to 50 years; 51 years) and by mutation status (BRCA1 v BRCA2). We also compared the risk of contralateral breast cancer for subgroups defined by each of the four treatments individually (ie, tamoxifen v no tamoxifen, oophorectomy v no oophorectomy, and so on) and in combination. Hazard ratios (HRs) were estimated using the Cox proportional hazards model, implemented in SAS (SAS Institute, Cary, NC). The HRs were adjusted for age, mutation status (BRCA1 v BRCA2), and other treatments received. RESULTS There were 491 women who were treated for stage I or II breast cancer between 1975 and There were 327 women from families with a BRCA1 mutation, and 152 women from families with a BRCA2 mutation. Twelve women carried a mutation in both genes. The characteristics of the 491 women with breast cancer included in the analysis are presented in Table 1, the characteristics of their tumors are detailed in Table 2, and the treatments they received are presented in Table 3. The majority of the subjects were treated with breastconserving surgery (39%) or with unilateral mastectomy (52%), but 44 women (9%) were initially treated with a bilateral mastectomy. One hundred six women had a contralateral preventive mastectomy at various times after the initial surgery (range, 1 month to 14 years). However, three women had had their contralateral breast removed before their first diagnosis of invasive breast cancer (two because of ductal carcinoma in situ, and one because of fibrocystic disease). These three women were observed for contralateral breast cancer after their diagnosis of invasive cancer, and were included with the women who had bilateral mastectomies. Of the nine women with bilateral synchronous
3 Metcalfe et al Table 1. Characteristics of 491 Study Subjects Patients Characteristic No. % Year of birth Year 1947 Range Age of diagnosis, years Mean 42.1 Range Age of diagnosis, years Mutation BRCA BRCA Both Place of residence Canada United States Genetic testing Yes, positive Not done Vital status Living Deceased Table 2. Characteristics of 491 Breast Cancers in the Study Characteristic No. % Stage I II Size, cm Grade I II III Unknown ER status Positive Negative Equivocal Unknown Lymph node status Positive Negative Laterality Unilateral Bilateral Histology Medullary Ductal Lobular Other Unknown NOTE. In the case of the nine women with synchronous bilateral tumors, only the first of the tumors that was recorded in the database is included here. Abbreviation: ER, estrogen receptor. breast cancer, seven had bilateral mastectomy, and two had bilateral breast-conserving surgery. These nine women were not at risk for contralateral breast cancer and are excluded from the following analyses. There were 209 women who had an oophorectomy, either for treatment of breast cancer, for the prevention of ovarian cancer, or for another reason. The exact indication for the oophorectomy was not known. After a mean follow-up period of 9.2 years, one contralateral breast cancer (in the chest wall) occurred among the 146 women treated with bilateral, prior, or delayed contralateral mastectomy. In contrast, there were 97 contralateral breast cancers diagnosed among the 336 women who retained the contralateral breast (HR, 0.03; P.0005). Because the observed risk of contralateral breast cancer following mastectomy was so low, the following analyses are restricted to the 336 women for whom the contralateral breast was intact. The mean interval between the diagnosis of the first breast cancer and the diagnosis of the contralateral breast cancer was 5.5 years (range, 0.1 to 16.2 years). The 5-year actuarial risk of contralateral breast cancer was 16.9% (95% CI, 10.5% to 23.3%), and the 10-year risk of breast cancer was 29.5% (95% CI, 20.6% to 38.3%). The risk of contralateral breast cancer was estimated for patient subgroups defined by age, gene (BRCA1 v BRCA2), and by treatment received (surgery, chemotherapy, tamoxifen, ovarian ablation). The univariate and multivariate HRs associated with each of these factors are presented in Table 4. The 10-year risk was slightly, but not significantly, higher for women with BRCA1 mutations (32%) than for women with BRCA2 mutations (24.5%; Fig 1). The risk was also slightly higher for women younger than 50 years at first breast cancer diagnosis (31%) compared with those diagnosed after age 50 years (23.5%; Fig 2). Neither radiotherapy nor chemotherapy use modified the risk significantly, but there was a moderate and borderline-significant decrease in the risk of contralateral breast cancer associated with tamoxifen use (HR, 0.59; 95% CI, 0.35 to 1.01; P.05). After adjustment for age, mutation, and other treatments, the reduction associated with tamoxifen was no longer significant (HR, 0.62; P.12). One hundred seven of the 336 women with an intact contralateral breast had a bilateral oophorectomy at some time; 14 women had an oophorectomy before breast cancer (13%); 15 women had an oophorectomy within 1 year of the diagnosis of breast cancer (14%); and 78 women had an oophorectomy from 1 year to 25 years after their initial 2330 JOURNAL OF CLINICAL ONCOLOGY
4 BRCA Mutations and Contralateral Breast Cancer Table 3. Characteristics of Treatments Received Among 482 Women With Unilateral Breast Cancer Treatment No. % Surgical Lumpectomy Unilateral mastectomy Bilateral mastectomy Chemotherapy Yes No Missing Tamoxifen Yes No Missing Oophorectomy Never Ever Missing Timing of oophorectomy Prior to diagnosis After diagnosis Missing Radiotherapy Yes No Missing Fig 1. Actuarial risks of contralateral breast cancer in carriers of BRCA1 and BRCA2 mutations. Dx, diagnosis. breast cancer diagnosis. To adjust for the effects of the timing of oophorectomy, oophorectomy was treated as a time-dependent covariate in the survival analysis. Oophorectomy was associated with a 59% reduction in the risk of contralateral breast cancer (HR, 0.41; 95% CI, 0.18 to 0.90). The magnitude of the risk reduction observed with oophorectomy was greater for women younger than 50 years at diagnosis (HR, 0.24; 95%CI, 0.07 to 0.77; P.02) than for women 50 years or older (HR, 0.91; 95% CI, 0.26 to 3.21). There was only a modest difference in the risk of contralateral breast cancer for women who had their oophorectomy before or at the time of diagnosis (HR, 0.32; P.12) and those who had their oophorectomy after initial breast cancer surgery (HR, 0.50; P.15). All factors were considered Factor Table 4. Risks of Contralateral Breast Cancer Associated With Selected Factors Univariate Multivariate HR 95% CI P HR 95% CI P BRCA 0.47 to to BRCA BRCA Age, years 0.36 to to Oophorectomy 0.21 to to Yes Chemotherapy 0.68 to to Yes Radiotherapy 0.51 to to Yes Tamoxifen 0.35 to to Yes NOTE. Multivariate estimates are adjusted for age, mutation (BRCA1 or BRCA2), and other treatments. Analyses restricted to 336 women with intact contralateral breast. Abbreviation: HR, hazard ratio
5 Metcalfe et al Fig 2. Actuarial risks of contralateral breast cancer in BRCA carriers diagnosed prior to or after age 50 years. Dx, diagnosis. Fig 3. Actuarial risks of contralateral breast cancer in BRCA carriers with either tamoxifen or oophorectomy, compared with carriers receiving neither treatment. Dx, diagnosis. jointly in a multivariate analysis, but oophorectomy was found to be the only intervention protective against contralateral breast cancer at a statistical level of significance (HR, 0.41; P.03). Because women who took tamoxifen or had an oophorectomy experienced lower risks of contralateral breast cancer, the cumulative risk was re-estimated in women who did not receive either of these adjuvant hormonal treatments. This estimate accurately represents the underlying risk for contralateral breast cancer owing to the presence of the susceptibility gene in the absence of intervention. For BRCA1 carriers, the 5-year actuarial risk was 27.1%, and the 10-year risk was 43.4%. For BRCA2 carriers, the 5-year actuarial risk was 23.5%, and the 10-year risk was 34.6%. In comparison, the 10-year risks for women who used tamoxifen or who had an oophorectomy were 18.8% for BRCA1 carriers and 13.1% for BRCA2 carriers. The HR associated with either of these hormonal treatments, compared with neither treatment, was 0.41 (95% CI, 0.24 to 0.70; P.001; Fig 3). For women diagnosed before age 50 years, the HR associated with the combination of tamoxifen and oophorectomy was 0.09 (95% CI, 0.01 to 0.68; P.02). The risk reduction associated with tamoxifen treatment was similar for BRCA1 and BRCA2 carriers (Tables 5 and 6). Oophorectomy seemed to be more effective for BRCA1 carriers than for BRCA2 carriers, but the CIs were wide. Because the tumor estrogen receptor (ER) status was missing for many women, it was not possible to estimate the effects of hormonal therapies separately for the subgroup of ER-negative breast cancer patients. We did not see a reduction in contralateral breast cancer risk associated with chemotherapy (Tables 4, 5, and 6). Among women younger than 50 years, who may have undergone early menopause due to chemotherapy, the HR for contralateral breast cancer was 0.92 (95% CI, 0.58 to 1.45). Information was available on ipsilateral cancers for 188 of 191 women who had breast-conserving surgery. It was not possible to distinguish between local recurrences and new primary ipsilateral cancers, and therefore, the number of observed events represents the sum of these two categories. The 10-year risk of ipsilateral cancer was 11.5% for BRCA1 carriers and BRCA2 carriers combined (9.8% for BRCA1 carriers and 14.6% for BRCA2 carriers). The 10- year risk of ipsilateral cancer was 9.1% for 171 women who received radiotherapy, and was 33.8% for 17 women who did not receive radiotherapy (HR, 0.23; P.01; Fig 4). Tamoxifen use and chemotherapy were also associated with a reduction in the risk of ipsilateral breast cancer in the univariate analysis (Table 7). DISCUSSION We report a high risk of contralateral breast cancer among 491 women with breast cancer and for whom a BRCA1 or BRCA2 mutation was documented in the family. We estimate the 5-year actuarial risk of contralateral breast cancer to be 17%, and the 10-year risk to be 30%. Previous studies have been much smaller in size. Pierce et al 4 estimated the 5-year contralateral rate of breast cancer to be 20% in a historical cohort of 71 BRCA carriers. Chappuis et al 5 estimated the 5-year risk of contralateral breast cancer to be 10% in a study of 32 carriers. Haffty et al 7 estimated the 12-year risk of contralateral breast cancer to be 42% in a study of 22 women with BRCA mutations. We found the 10-year risk of contralateral breast cancer to be modestly greater for women diagnosed before age 50 years than after age 50 years. Verhoog et al 6 estimated the 10-year risk of contralateral breast cancers among 124 BRCA1 carriers diagnosed before age 50 years to be 40%, versus 12% for 40 patients diagnosed after age 50 years. Robson 2332 JOURNAL OF CLINICAL ONCOLOGY
6 BRCA Mutations and Contralateral Breast Cancer Factor Table 5. Risks of Contralateral Breast Cancer Associated With Selected Factors (BRCA1 carriers) Univariate Multivariate HR 95% CI P HR 95% CI P Age, years 0.33 to to Oophorectomy 0.16 to to Yes Chemotherapy 0.60 to to Yes Radiotherapy 0.56 to to Yes Tamoxifen 0.26 to to Yes NOTE. Multivariate estimates are adjusted for age, mutation, and other treatments. Analyses restricted to 224 women with an intact contralateral breast. Abbreviation: HR, hazard ratio. et al 3 estimated the 5-year risk of contralateral breast cancer to be 31% in a group of 30 BRCA carriers diagnosed before age 42 years. The current study has strengths in addition to its large sample size. All women with breast cancer in the BRCA mutation positive families were identified, and those who had been diagnosed with breast cancer from 1975 to 2000 at 65 years or younger were eligible to enter the study population. Eighty women with breast cancer who had not had genetic testing were included; however, women who had tested negative were excluded. We included untested and deceased women in the study in order to avoid the survivorship bias that would arise if only tested women were included. The majority of genetic tests were done several years after the diagnosis of breast cancer. Restricting the study population to living women who were available for testing would inevitably have introduced a survivorship bias. However, given the presence of a documented mutation in all of the study families, the inclusion of untested women should not introduce significant misclassification bias. Of the 430 women with breast cancer in known BRCA-positive families who received genetic testing, 411 (96%) were found to be mutation carriers, and 19 (4%) were found to be noncarriers. Forty-three of the 80 untested women were de- Factor Table 6. Risks of Contralateral Breast Cancer Associated With Selected Factors (BRCA2 carriers) Univariate Multivariate HR 95% CI P HR 95% CI P Age, years 0.27 to to Oophorectomy 0.13 to to Yes Chemotherapy 0.51 to to Yes Radiotherapy 0.22 to to Yes Tamoxifen 0.33 to to Yes NOTE. Multivariate estimates are adjusted for age, mutation, and other treatments. Analyses restricted to 112 women with an intact contralateral breast. Abbreviation: HR, hazard ratio
7 Metcalfe et al Fig 4. Actuarial risks of ipsilateral breast cancer in BRCA carriers with breast-conserving surgery, with and without radiotherapy (Radio.). Dx, diagnosis. ceased (54%). The average age of diagnoses of both the tested and untested women was 42.2 years. However, compared with the tested women, the untested women were more likely to have stage II tumors (64% v 51%). Bilateral breast cancer was not among the eligibility criteria for genetic testing in the participating centers. However, if families with members with bilateral breast cancer were more likely to seek and to obtain genetic testing than families with single primary cancers only, then our study sample would be enriched for women with bilateral cancers. This would have the effect of spuriously raising the estimate of the contralateral cancer risk. This is a potential bias among all studies reported to date, but this problem will be lessened for purely prospective studies. There was a clear and dramatic benefit of contralateral mastectomy in terms of cancer incidence. Future studies will be required to determine whether this confers a benefit in terms of mortality. We also found the risk of contralateral cancer to be reduced when there was a history of either oophorectomy or use of tamoxifen, in keeping with the results of our earlier case-control study. 8 The combination of the two was particularly effective among young women (HR, 0.09; 95% CI, 0.01 to 0.68). This degree of protection is perhaps surprising, given that the majority of these tumors (approximately 60%) will be ER-negative (Table 2). Unfortunately, we did not obtain data on the ER status of the contralateral tumors and data on ER status was missing for many of the tumors diagnosed before The observed protective effect of tamoxifen was slightly greater for the BRCA1 carriers (HR, 0.57) than for the BRCA2 carriers (HR, 0.73; Tables 5 and 6), but this difference was not statistically significant. Our findings have important implications for the primary prevention of hereditary breast cancer. It is now generally well accepted that oophorectomy protects against breast cancer in BRCA carriers, 9,10 but the role of tamoxifen remains controversial. King et al 11 found no primary protective role for tamoxifen against BRCA1-associated breast cancer, but the study included only eight carriers with breast cancer. In our study the observed magnitude of the protective effect was larger for oophorectomy (59%) than Factor Table 7. Risks of Ipsilateral Breast Cancer Associated With Selected Factors Univariate Multivariate HR 95% CI P HR 95% CI P BRCA 0.37 to to BRCA BRCA Age, years 0.65 to to Oophorectomy 0.11 to to Yes Chemotherapy 0.07 to to Yes Radiotherapy 0.09 to to Yes Tamoxifen 0.02 to to No Yes NOTE. Multivariate estimates are adjusted for age, mutation (BRCA1 or BRCA2), and other treatments. Abbreviation: HR, hazard ratio JOURNAL OF CLINICAL ONCOLOGY
8 BRCA Mutations and Contralateral Breast Cancer for tamoxifen (38%). Potential benefits of oophorectomy in the management of primary breast cancer include reduction in risk of contralateral breast cancer, reduction in risk of primary breast cancer recurrence, and in prevention of primary ovarian cancer. Ovarian ablation has been shown to be an effective treatment for premenopausal breast cancer. In a large meta-analysis of women treated for breast cancer younger than 50 years, 15-year survival after breast cancer improved from 46% to 52% with ovarian ablation. 12 We also observed a (nonsignificant) reduction in the risk of ipsilateral breast cancer with oophorectomy (OR, 0.33), but it has not yet been established whether oophorectomy impacts on total mortality in this situation. These studies are now underway. It has been suggested that BRCA1-associated tumors show enhanced chemosensitivity. This may be related to their rapid growth rate and the impaired ability of BRCAdeficient cells to repair double stranded DNA breaks. 13 In the present study, we saw a protective effect of chemotherapy on the risk of ipsilateral cancer (Table 7) but not on the risk of contralateral cancer (Table 4). In contrast, a strong protective effect of chemotherapy on contralateral breast cancer risk was seen in our case-control study. 8 The reason for the observed discrepancy between the two studies is unknown, but some of the variation may be due to chance. It has also been speculated that radiotherapy (or mammography) may be hazardous to BRCA carriers because of the potential for increased mutability due to impaired DNA repair. Despite this theoretical concern, radiotherapy treatment was associated with a significant decrease in the risk of ipsilateral cancer following breast-conserving surgery in BRCA mutation carriers. Among patients treated for breast cancer with breast-conserving surgery and radiotherapy, the 10-year risk of contralateral breast cancer (27.4%) greatly exceeded that of ipsilateral cancer (11.5%). This was largely due to the protective effect of radiotherapy on ipsilateral breast cancer (HR, 0.29) but not on contralateral breast cancer (HR, 1.02). Chappuis et al 5 also reported a higher 5-year rate of contralateral breast cancer (10%) than of ipsilateral cancers (6%) in a study of 32 BRCA carriers. In contrast Haffty et al 7 reported similar high rates of ipsilateral (49%) and contralateral (42%) cancers in BRCA carriers at 12 years, but their study was small (22 carriers). In the present study, the rate of contralateral breast cancer in subjects with breast tissue at risk was similar to the rate of ipsilateral cancer observed in the small group of women who did not receive radiotherapy as part of their initial breast cancer treatment (Fig 4). This suggests that radiotherapy following breast-conserving surgery is valuable for prevention of local recurrence in BRCA carriers. We saw no evidence of a hazardous effect of radiotherapy for contralateral or ipsilateral breast cancers throughout the course of this study, but it will be important to follow-up all patients in this cohort for a longer period before the longterm effects of radiotherapy can be properly assessed. Patients with hereditary susceptibility to breast cancer are generally treated according to protocols established for nonhereditary forms of cancer (ie, most premenopausal women with ER-negative, high-grade tumors of 2cmin diameter are offered breast-conserving surgery and adjuvant chemotherapy, but not ovarian ablation or tamoxifen). In this scenario, the risk of contralateral breast cancer is approximately 4% per year, or 40% at 10 years. The risk of contralateral cancer is almost zero for women who undergo bilateral mastectomy, and is decreased for women who undergo oophorectomy or are treated with tamoxifen. Authors Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES 1. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: , Verhoog LC, Brekelmans CTM, Synaeve C, et al: Survival and tumor characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351: , Robson M, Gilewki T, Haas B, et al: BRCAassociated breast cancer in young women. J Clin Oncol 16: , Pierce LJ, Strawderman M, Narod SA, et al: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18: , Chappuis PO, Kapusta L, Begin LR, et al: Germline BRCA1/2 mutations and p27kip protein levels independently predict outcome after breast cancer. J Clin Oncol 18: , Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83: , Haffty BG, Harrold E, Khan AJ, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359: , Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Lancet 356: , Rebbeck TR, Levin AM, Eisen A, et al: Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. JNCI 91: , Rebbeck TR, Lynch HT, Neuhausen SL, et al: Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 346: , King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. JAMA 286: , Early Breast Cancer Trialists Collaborative Group: Ovarian ablation in early breast cancer: Overview of the randomized trials. Lancet 348: , Hoeijmakers JH: Genomic maintenance mechanisms for preventing cancer. Nature 441: ,
The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
Gynecologic Oncology 96 (2005) 222 226 www.elsevier.com/locate/ygyno The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Kelly A. Metcalfe a,b, *, Henry T. Lynch c, Parviz Ghadirian
More informationEffect of Oophorectomy on Survival After Breast Cancer
Research Original Investigation Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, PhD; Henry T. Lynch, MD; William D. Foulkes, MBBS, PhD; Nadine
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 7 MARCH 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prophylactic in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study
More informationEffect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Hereditary Cancer in Clinical Practice 2005; 3(2) pp. 53-57 Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly A. Metcalfe 1, 2, William
More informationGlobal Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium April 24 th, 2015 The Shilla Jeju Hotel, Jeju Island, Korea
Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium April 24 th, 2015 The Shilla Jeju Hotel, Jeju Island, Korea Dr. Steven A. Narod MD, FRCPC Canada Research Chair in Breast
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationBreast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationINTRODUCTION BREAST CANCER CARE
INTRODUCTION Breast Cancer Care welcomes the HFEA s consultation on embryo selection for inherited cancer. This is an extremely important and complex issue. Because of this, Breast Cancer Care has encouraged
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationNHOLUA. September 20, 2016 Lincoln, NE
NHOLUA September 20, 2016 Lincoln, NE UNDERWRITING BREAST CANCER, A NEW APPROACH Dr Robert Lund Basics in Determination of Breast Cancer Prognosis Age at Diagnosis Tumor Size Lymph Node Status Title of
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationImpact of Oophorectomy on Cancer Incidence and
Published Ahead of Print on February 24, 2014 as 10.1200/JCO.2013.53.2820 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2013.53.2820 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L
More informationTITLE: Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer
AD Award Number: DAMD17-01-1-0325 TITLE: Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer PRINCIPAL INVESTIGATOR: Mark E. Robson, M.D. CONTRACTING
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationAccuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer
Accuracy of the BRCAPRO Model Among Women With Bilateral Breast Cancer Kaylene J. Ready, MS 1, Kristen J. Vogel, MS 2, Deann P. Atchley, PhD 1, Kristine R. Broglio, MS 1, Kimberly K. Solomon, MBA 1, Christopher
More informationPolicy #: 259 Latest Review Date: November 2009
Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationThe New England Journal of Medicine PROPHYLACTIC OOPHORECTOMY IN CARRIERS OF BRCA1 OR BRCA2 MUTATIONS. Study Participants
PROPHYLACTIC OOPHORECTOMY IN CARRIERS OF BRCA1 OR BRCA2 MUTATIONS TIMOTHY R. REBBECK, PH.D., HENRY T. LYNCH, M.D., SUSAN L. NEUHAUSEN, PH.D., STEVEN A. ROD, M.D., LAURA VAN T VEER, PH.D., JUDY E. GARBER,
More informationBruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationInherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions
Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationBreast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy
Breast Cancer Risk Perception Among Women Who Have Undergone Prophylactic Bilateral Mastectomy Kelly A. Metcalfe, Steven A. Narod Background: Prophylactic bilateral mastectomy is a preventive option for
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationBRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview
BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary
More informationOral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Steven A. Narod, Marie-Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T. Lynch, Parviz Ghadirian, Diane Provencher, Ketil
More informationPerception of Screening and Risk Reduction Surgeries in Patients Tested for a BRCA Deleterious Mutation
Perception of Screening and Risk Reduction Surgeries in Patients Tested for a BRCA Deleterious Mutation Jennifer K. Litton, MD 1, Shannon N. Westin, MD 2, Kaylene Ready, CGC 1, Charlotte C. Sun, MD 2,
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2015 Section: Surgery Place(s) of Service:
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationScreening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women
Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women Background About 5% of women in Canada with breast cancer and about 12% of women with ovarian cancer, are born with an inherited
More informationThe New England Journal of Medicine ORAL CONTRACEPTIVES AND THE RISK OF HEREDITARY OVARIAN CANCER. Subjects
ORAL CONTRACEPTIVES AND THE RISK OF HEREDITARY OVARIAN CANCER STEVEN A. NAROD, M.D., HARVEY RISCH, M.D., PH.D., ROXANA MOSLEHI, M.SC., ANNE DØRUM, M.D., SUSAN NEUHAUSEN, PH.D., HAKAN OLSSON, M.D., DIANE
More informationBreast cancer is the most frequently
Charmaine Kim-Sing, MBChB, FRCPC, Lorna Weir, MD, FRCPC, and Urve Kuusk, MD, FRCPC Breast cancer risk management for moderaterisk and high-risk women An accurate assessment of breast cancer risk can help
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationNo Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
Hereditary Cancer in Clinical Practice 2007; 5(2) pp. 67-71 No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers Pål Møller 1, Lovise Mºhle 1, Neal Clark 1, Jaran Apold 2 1 Section
More informationThe best way of detection of and screening for breast cancer in women with genetic or hereditary risk
The best way of detection of and screening for breast cancer in women with genetic or hereditary risk Ingrid Vogelaar Introduction Each year almost 1.2 million women are diagnosed with breast cancer worldwide.
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationMETASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER
Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationTamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study Steven A Narod, Jean-Sébastien Brunet, Parviz Ghadirian, Mark Robson, Ketil Heimdal, Susan L
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationTwenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status
Twenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status Payal D. Shah, MD 1 ; Sujata Patil, PhD 2 ; Maura N. Dickler, MD
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
More informationCurrent Strategies in the Detection of Breast Cancer. Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF
Current Strategies in the Detection of Breast Cancer Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF Outline ν Screening Film Mammography ν Film ν Digital ν Screening
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationEligibility criteria for prophylactic treatment allowance
Eligibility criteria for prophylactic treatment allowance Southern Cross will only pay the prophylactic treatment allowance for the following healthcare services when the applicable eligibility criteria
More informationFactors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women
Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2010 Factors Associated with Early Versus Late
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationOverview of Inherited Cancer
Sidorela Gllava Overview of Inherited Cancer 52% 32% 16% BRCA 1 BRCA 2 Other Genes Breast Cancer: p53, PTEN, etc Ovarian Cancer:MSH2, MSH6, MLH1, etc Breast and Ovarian Cancer Risk: BRCA Mutation Carriers
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationAudit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.
National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationCa in situ e ormonoterapia. Discussant : LORENZA MARINO
Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationW3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability
W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION A Population-Based Study of Bilateral Efficacy in Women at Elevated Risk for Breast Cancer in Community Practices Ann M. Geiger, PhD; Onchee Yu, MS; Lisa J. Herrinton, PhD; William
More informationProphylactic mastectomy, a look at the problem
www.clinicaloncology.com.ua 1 Prophylactic mastectomy, a look at the problem I.I.Smolanka, S.Y.Skliar, A.D.Loboda The National Cancer Institute, Kiev Summary: The question of the bilateral prophylactic
More informationApproximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since. By Dawna Gilchrist, MD, FRCPC, FCCMG
By Dawna Gilchrist, MD, FRCPC, FCCMG Approximately 5% to 10% of breast cancer (BC) is hereditary in nature. Since the discovery of the genes BRCA 1 and 2 in the early 1990s, genetic counselling and testing
More informationPopulation-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a
VOLUME 28 NUMBER 14 MAY 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationPatient Education. Breast Cancer Prevention. Cancer Center
Patient Education Breast cancer affects one in nine women in the US by the time they reach their 80 s. It is the result of several mutations or alterations in the genes found in the DNA of normal breast
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationClinical Considerations in the Management of Individuals at Risk for Hereditary Breast and Ovarian Cancer
Recognition of a potential hereditary predisposition for breast and ovarian cancer allows the implementation of a specialized surveillance program to manage subsequent cancer risk. James Rosenquist. Shriek,
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationSuccessful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer
Familial Cancer (2010) 9:321 325 DOI 10.1007/s10689-010-9344-7 Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer Karijn P. M. Suijkerbuijk Elsken van der Wall
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer
More informationDuctal Carcinoma in Situ (DCIS)
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Versions 2002 2017: Audretsch / Blohmer / Brunnert / Budach /
More informationManaging the Breast in Patients Who Test Positive for Hereditary Breast Cancer
Ann Surg Oncol (2012) 19:1738 1744 DOI 10.1245/s10434-012-2258-x EDUCATIONAL REVIEW RISK ASSESSMENT AND GENETIC TESTING FOR HEREDITARY BREAST CANCER Managing the Breast in Patients Who Test Positive for
More information